Amgen spent $2.82 million on lobbying in 3Q – AP – msnbc.com
Under the health reform law of 2010, the FDA is instructed to give new biotechnology drugs 12 years of competitive protection from biosimilars. The framework was considered a major victory for Amgen and other biotech companies looking to preserve profits ...
Subscribe to LegalLaw247.Com Newsletter
